Deals and Data
As flu season approaches, vaccine makers are rushing to respond to the threat of the HIN1 virus, or swine flu. The efforts of two San Diego companies are included in the front page Sunday story in the Union-Tribune. Meanwhile, Novartis reported it has started human clinical trials of its swine flu therapy.
Domain Associates raises $500 million for a life sciences investment fund.
The Anadys experimental therapy for hepatitis C shows promising result in an early stage study.
Wall Street analysts think Amgen’s new osteoporosis drug is a potential blockbuster.
GenomeWeb pointed out that in this US News & World Report article biotechnology is identified as a "core enabling technology of the 21st century in the way the microchip has become in the latter part of the 20th century," according to David Finegold, the dean of Rutgers University's School of Management and Labor Relations
Adventrx Pharmaceuticals said Aug. 4 that it intends to submit its experimental chemotherapy drug ANX-530 to the FDA before the end of the year.
San Diego’s Senomyx said it could get as much as $34.5 million through a new collaboration with Switzerland’s Firmenich, the largest private flavor and fragrance company in the world.
Biotech’s cash crunch has placed even more importance on angel investors. Voice of San Diego talked to some local angels about how their investment strategy has changed.
UCSD seeks patients for a phase 2 clinical trial of Alzheimer’s therapy.
Good news for diabetics with the FDA approval of a new therapy from Bristol-Myers Squibb and partner AstraZeneca.
San Diego-based Ichor Medical Systems gets $3.3 million grant for Alzheimer’s work.
La Jolla’s Genomics Institute of the Novartis Research Foundation said Aug. 5 it has entered into a research agreement with the Juvenile Diabetes Research Foundation to push treatments for type 1 diabetes into the clinic at a faster pace.
About 500 Oceanside workers responsible for producing batches of Genentech’s best-selling cancer drug Avastin will keep their jobs under a plan to merge the biotech behemoth into Swiss drug maker Roche and align the businesses’ manufacturing sites worldwide.
Diagnostic test maker Quidel is growing and the San Diego-based company has made some appointments in the ranks of its upper management
San Diego-based Zogenix and partner Astellas announce deal on marketing acute migraine therapy.
San Diego-based Vical and Teva Pharmaceuticals announced a sales and marketing deal in the melanoma market.
San Diego is ranked fourth on Entrepreneur magazine’s list of the top 10 U.S. cities that are conducive to starting or growing a business.
An experimental therapy developed in San Diego by Vertex Pharmaceuticals could be “the man on the moon” for cystic fibrosis treatments, according to a renowned scientist in the field.
San Diego-based Sequenom continues its internal investigation into mishandling of clinical trial data for its prenatal Downs Syndrome test, and reports it no longer will rely on previous data on the test.